Vitamin D deficiency is associated with coronary artery calcification in cardiovascularly asymptomatic African Americans with HIV infection

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 493-500

  Lai, Shenghan ^a,b   Fishman, Elliot K ^a   Gerstenblith, Gary ^a   Brinker, Jeffrey ^a   Tai, Hong ^a   Chen, Shaoguang ^a   Li, Ji ^b   Tong, Wenjing ^a   Detrick, Barbara ^a   Lai, Hong ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

African Americans; Antiretroviral therapy; Coronary artery calcification; HIV infection; Vitamin D deficiency

Indexed keywords

25 HYDROXYVITAMIN D; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; ARTICLE; CHOLESTEROL BLOOD LEVEL; COCAINE DEPENDENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; FRAMINGHAM RISK SCORE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PATIENT MONITORING; PREVALENCE; SEX DIFFERENCE; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

AFRICAN AMERICANS; ANTIRETROVIRAL THERAPY; CORONARY ARTERY CALCIFICATION; HIV INFECTION; VITAMIN D DEFICIENCY;

ADULT; AFRICAN AMERICANS; ASYMPTOMATIC DISEASES; BALTIMORE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIVARIATE ANALYSIS; ODDS RATIO; PREVALENCE; RISK FACTORS; VASCULAR CALCIFICATION; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84889849416     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S48388     Document Type: Article

References (60)

1. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-1430.
2. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:F167-F173.
3. Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS. 2001;12:463-468.
4. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29:21-31.
5. Friis-Møller N, Weber R, Reiss P, et al; DAD study group. Cardiovascular risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
6. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
7. Friis-Møller N, Sabin CA, Weber R, et al; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2004.
8. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
9. Clark LT, Ferdinand KC, Flack JM, et al. Coronary heart disease in African Americans. Heart Dis. 2001;3(2):97-108.
10. Harris SS. Does vitamin D deficiency contribute to increased rates of cardiovascular disease and type 2 diabetes in African Americans? Am J Clin Nutr. 2011;93(5):1175S-1178S.
11. Camargo CA Jr. Vitamin D and cardiovascular disease time for large randomized trials. J Am Coll Cardiol. 2011;58(14):1442-1444.
12. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52:1949-1956.
13. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503-511.
14. Lai H, Fishman E, Gerstenblith G, et al. Vitamin ddeficiency is associated with significant coronary stenoses in asymptomatic African American chronic cocaine users. Int J Cardiol. 2012;158(2):211-216.
15. Lai H, Detrick B, Fishman EK, et al. Vitamin D deficiency is associated with the development of subclinical coronary artery disease in African Americans with HIV infection: a preliminary study. J Investig Med. 2012;60(5):801-807.
16. Lai H, Gerstenblith G, Fishman EK, et al. Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection. Clin Infect Dis. 2012;54(12):1747-1755.
17. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336-1345.
18. Ersfeld DL, Rao DS, Body JJ, et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem. 2004;37:867-874.
19. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley and Sons; 1989.
20. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
21. Lai S, Fishman EK, Lai H, et al. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. Clin Infect Dis. 2008;46:600-610.
22. Meng Q, Lima JAC, Lai H, et al. Coronary artery calcification, atherogenic lipid changes and increased erythrocyte volume in HIV-1 infected participants treated with protease inhibitors. Am Heart J. 2002;144(4):642-648.
23. Meng Q, Lima JAC, Lai H, et al. Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. J Acquir Immune Defic Syndr. 2002;30:306-310.
24. Lai S, Lai H, Meng Q, et al. Effect of cocaine use on coronary calcification among black adults in Baltimore. Am J Cardiol. 2002;90:326-328.
25. Meng Q, Lima JA, Lai H, et al. Elevated C-reactive protein levels are associated with endothelial dysfunction in chronic cocaine users. Int J Cardiol. 2003;88:191-198.
26. Lai S, Lai H, Celentano DD, et al. Factors associated with accelerated atherosclerosis in hiv-1-infected persons treated with protease inhibitors. AIDS Patient Care STDS. 2003;17(5):211-219.
27. Tong W, Lima JA, Lai H, Celentano DD, Dai S, Lai S. Relation of coronary artery calcium to left ventricular mass in African Americans. Am J Cardiol. 2004;93:490-492.
28. Tong W, Lima JA, Meng Q, Flynn E, Lai S. Long-term cocaine use is related to cardiac diastolic dysfunction in an African-American population in Baltimore, Maryland. Int J Cardiol. 2004;97:25-28.
29. Lai S, Lima JA, Lai H, et al. Human immunodeficiency virus 1 infection, cocaine, and coronary calcification. Arch Intern Med. 2005;165:690-695.
30. Meng QY, Du JF, Lai H, Lai SH. Coronary artery calcification is associated with atherogenic lipid changes, cardiac dysfunction and morphologic abnormalities in HIV-1 infected black adults. Chin Med J (Engl). 2005;118(5):412-414.
31. Ren S, Tong W, Lai H, Osman NF, Pannu H, Lai S. Effect of long-term cocaine use on regional left ventricular function as determined by magnetic resonance imaging. Am J Cardiol. 2006;97:1085-1088.
32. Lai S, Bartlett J, Lai H, et al. Long-term combination antiretroviral therapy is associated with the risk of coronary plaques in African Americans with HIV infection. AIDS Patient Care STDs. 2009;23(10):815-824.
33. Garg H, Joshi A, Mukherjee D. Cardiovascular complications of HIV infection and treatment. Cardiovasc Hematol Agents Med Chem. 2013;11(1):58-66.
34. Périard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100(7):700-705.
35. Thomas CM, Smart EJ. How HIV protease inhibitors promote atherosclerotic lesion formation. Curr Opin Lipidol. 2007;18(5):561-565.
36. Jiang B, Hebert VY, Zavecz JH, Dugas TR. Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquir Immune Defic Syndr. 2006;42(4):391-395.
37. Chai H, Yang H, Yan S, et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr. 2005;40(1):12-19.
38. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
39. Behrens JM, Boerner AR, Weber K, et al. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest. 2002;110: 1319-1327.
40. Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest. 2003;111;389-397.
41. Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis. 2002;162:433-438.
42. Maillet M, Chiarasini D, Nahas G. Myocardial damage induced by cocaine administration of a week's duration in the rat. Adv Biosci. 1991;80:187-197.
43. Risner ME, Jones BE. Intravenous self-administration of cocaine and norcocaine by dogs. Psychopharmacology (Berl). 1980;71:83-89.
44. Langner RO, Perry LF, Heavilin D. The cardiovascular toxicity of cocaine in the rabbit (abstract). Fed Proc. 1983;42:1360.
45. Kolodgie FD, Virmani R, Rice HE, et al. Intravenous cocaine accelerates atherosclerosis in cholesterol-fed New Zealand White rabbits (abstract). J Am Coll Cardiol. 1990;15(2):217A.
46. Togna G, Tempesta E, Togna AR, Dolci N, Cebo B, Caprino L. Platelet responsiveness and biosynthesis of thromboxane and prostacyclin in response to in vitro cocaine treatment. Haemostasis. 1985;15: 100-107.
47. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96: 1911-1930.
48. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
49. Gelfand JM, Cree BA, McElroy J, et al. Vitamin D in African Americans with multiple sclerosis. Neurology. 2011;76(21):1824-1830.
50. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2009;205:255-260.
51. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol. 2009;20(8):1805-1812.
52. Reddy Vanga S, Good M, Howard PA, Vacek JL. Role of vitamin D in cardiovascular health. Am J Cardiol. 2010;106(6):798-805.
53. Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009;94:4023-4030.
54. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008;25:320-325.
55. Tare M, Emmett SJ, Coleman HA, et al. Vitamin D insufficiency is associated with impaired vascular endothelial and smooth muscle function and hypertension in young rats. J Physiol. 2011;589(Pt 19): 4777-4786.
56. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol. 2007;18(1):41-46.
57. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr. 2003;89(5):552-572.
58. Zehnder D, Bland R, Chana RS, et al. Synthesis of 1, 25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002;13(3):621-629.
59. Spence LA, Weaver CM. Calcium intake, vascular calcification, and vascular disease. Nutr Rev. 2013;71(1):15-22.
60. Reid IR, Bolland M, Avenell A, Grey A. Cardiovascular effects of calcium supplementation. Osteoporos Int. 2011;22:1649-1658.